Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Diverse cultures, radiance of gloryInternet drama about lost artifacts touches Chinese netizensTourism boom promotes revitalization of intangible cultural heritageChina's space environment monitoring satellites sent into spaceSpaceX launches 23 more Starlink internet satellites into spaceChinese tech firms strive for leadership in global eChinese, Brazilian scientists name new flying reptiles to mark collaborationFeature: AI system developed by students helps missing children return homeInt'l scientists conduct joint experiments with China's artificial sun teamChina prepares to launch Tianzhou
2.2528s , 6500.84375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Guide news portal